Recombinant allergens: What does the future hold?

This year we are celebrating not only the centenary of allergen-specific immunotherapy but also the 10-year anniversary of the first administration of recombinant allergen–based vaccines to allergic patients. By using recombinant DNA technology, defined and safe allergy vaccines can be produced that...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2011-04, Vol.127 (4), p.860-864
Main Authors: Valenta, Rudolf, MD, Niespodziana, Katarzyna, MSc, Focke-Tejkl, Margit, PhD, Marth, Katharina, MD, Huber, Hans, PhD, Neubauer, Angela, PhD, Niederberger, Verena, MD
Format: Article
Language:English
Subjects:
allergen-specific immunotherapy
Allergens - immunology
Allergens - therapeutic use
Allergies
Allergy
Allergy and Immunology
Animals
Biological and medical sciences
Clinical trials
Desensitization, Immunologic - trends
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Hepatitis
Humans
Hypersensitivity - immunology
Hypersensitivity - prevention & control
Immunization
Immunopathology
Immunotherapy
Lymphocytes
Medical sciences
Peptides
Proteins
recombinant allergen
Recombinant Proteins - immunology
Recombinant Proteins - therapeutic use
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Studies
Vaccines
Vaccines - immunology
Vaccines - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This year we are celebrating not only the centenary of allergen-specific immunotherapy but also the 10-year anniversary of the first administration of recombinant allergen–based vaccines to allergic patients. By using recombinant DNA technology, defined and safe allergy vaccines can be produced that allow us to overcome many, if not all, of the problems associated with the use of natural allergen extracts, such as insufficient quality, allergenic activity, and poor immunogenicity. Here we provide an update of clinical studies with recombinant allergen–based vaccines, showing that some of these vaccines have undergone successful clinical evaluation up to phase III studies. Furthermore, we introduce a strategy for allergen-specific immunotherapy based on recombinant fusion proteins consisting of viral carrier proteins and allergen-derived peptides without allergenic activity, which holds the promise of being free of side effects and eventually being useful for prophylactic vaccination.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2011.02.016